Welcome to the third segment of Big Health Talks, where we speak with clinical experts and benefits leaders about trends, challenges, and solutions in mental health care and the field of digital therapeutics (DTx).
In this episode, Jenna Carl, PhD, Chief Medical Officer at Big Health, is joined by Anu Asaani, PhD, Assistant Professor of Clinical Psychology at the University of Utah. They discuss everything you need to know about generalized anxiety disorder (GAD): what it is, who it affects, standard care options, myths and misconceptions, and predictions for the evolution of DTx as an effective treatment in the coming years.
What is GAD, and who does it affect?
What are the common treatments for GAD?
It seems to be a common myth that patients want medication as a quick fix for GAD. What is your experience with this?
Dr. Asaani is a paid consultant for Big Health.
During the COVID-19 public health emergency, Daylight is being made available as a treatment for generalized anxiety disorder (GAD) without a prescription. Daylight has not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of GAD.
DOC-3060 Effective 08/2023
Here’s our latest
Supporting the mental health of your organization amid rising suicide rates
Understand how organizational changes can positively impact and address the growing mental health crisis.
Improving member outcomes for mental health conditions with evidence-based digital treatments
Rooted in cognitive behavioral therapy, clinically validated, proprietary treatments offer members proven alternatives to achieve remission.
DTx: value, impact, and expansion
In our second episode of Big Health Talks, we discuss how digital therapeutics transform patient care with a consultant pharmacist.
